Exploring populations with special genetic characteristics for drug research
CompanyVariant Bio, Seattle, USA
To optimize active ingredient research and drug development, Variant Bio conducts human genetic studies in collaboration with numerous research partners worldwide. The company takes a unique approach by combining anthropological, epidemiological and genetic findings. In its population genetic analyses, the company focuses in particular on underrepresented population groups that have special health-related characteristics and/or rare genetic variants at high frequencies. The current pipeline includes multiple programs at various stages of development to identify therapeutic targets and potential drug candidates. The focus of the pipeline is on the development of drugs to treat severe fibrotic, immunological, liver and kidney diseases for which there are not yet sufficient drug therapy options. Research into previously unconsidered genetic populations and cohorts shows high potential for generating new knowledge. By developing patient-specific algorithms and using state-of-the-art analysis techniques from various biomedical research areas, the company's large-scale biodatabase and screening platform helps to accelerate drug discovery and optimize patient medication care in a personalized manner.
Human genetics has the power to transform drug development
info@variantbio.com
Added on: 04-24-2024
[1] https://www.variantbio.com/our-work[2] https://www.variantbio.com/pipeline
